血必净治疗多器官功能障碍综合征疗效的Meta分析
该系统评价检索PubMed、Cochrane Library、Embase、CNKI、CBM、VIP和万方数据库至2018年3月4日,纳入35项RCT共2131例MODS患者(试验组1076例、对照组1055例),比较血必净联合常规西医治疗与单用常规西医治疗。Meta分析显示联合血必净可降低7天死亡率(OR=0.42,99%CI 0.26-0.69,P<0.00001)和28天死亡率(OR=0.31,99%CI 0.21-0.45,P<0.00001),并降低APACHE II评分(MD=3.24,99%CI 2.00-4.49)和Marshall评分(MD=1.95,99%CI 0.50-3.40)。联合治疗在清除IL-6、TNF-α、提升血小板和改善PT方面优于对照组,但APTT改善无显著优势(MD=0.96,99%CI -5.08-7.00,P=0.68)。作者认为血必净可能通过清除细胞因子、提升血小板和改善凝血来保护MODS患者器官功能,从而降低死亡率、改善预后。
要点
- 纳入35项RCT共2131例MODS患者,血必净联合常规治疗组1076例 vs 常规治疗组1055例。
- 联合血必净组7天死亡率OR=0.42(99%CI 0.26-0.69,P<0.00001),28天死亡率OR=0.31(99%CI 0.21-0.45,P<0.00001),均低于对照组。
- 联合血必净组APACHE II评分MD=3.24(99%CI 2.00-4.49)、Marshall评分MD=1.95(99%CI 0.50-3.40),均低于对照组。
- 联合血必净组IL-6(MD=5.56,99%CI 1.44-9.68)、TNF-α(MD=4.97,99%CI 3.44-6.50)、血小板(MD=-50.79,99%CI -74.84至-26.74)、PT(MD=4.55,99%CI 3.96-5.14)改善优于对照组;APTT无显著优势(MD=0.96,99%CI -5.08-7.00,P=0.68)。
- 漏斗图效应点基本对称,但纳入研究数量较少,文献偏倚不能完全排除。
适用人群与场景
- 多器官功能障碍综合征(MODS)患者,纳入35项RCT共2131例,试验组1076例、对照组1055例。
处置流程与药物剂量
- 对照组接受常规西医治疗,包括病因治疗、抗生素、机械通气、营养支持以及维持液体、电解质和酸碱平衡的综合治疗。
- 试验组在常规西医治疗基础上联合血必净注射液。
研究设计与关键结果
- 系统评价纳入35项RCT共2131例MODS患者(试验组1076例、对照组1055例),比较血必净联合常规治疗与单用常规治疗。
- 7天死亡率:联合血必净组OR=0.42(99%CI 0.26-0.69,P<0.00001);28天死亡率:OR=0.31(99%CI 0.21-0.45,P<0.00001)。
- APACHE II评分MD=3.24(99%CI 2.00-4.49,P<0.00001);Marshall评分MD=1.95(99%CI 0.50-3.40,P=0.0005)。
- IL-6 MD=5.56(99%CI 1.44-9.68,P=0.0005);TNF-α MD=4.97(99%CI 3.44-6.50,P<0.00001);血小板MD=-50.79(99%CI -74.84至-26.74,P<0.0001);PT MD=4.55(99%CI 3.96-5.14,P<0.00001)。
- APTT改善无显著优势:MD=0.96(99%CI -5.08-7.00,P=0.68)。
- 漏斗图显示各研究效应点主要集中于合并效应量附近,倒漏斗图基本对称分布;但因纳入研究数量较少,文献偏倚不能完全排除。
证据类型、等级与局限
- 证据类型:系统评价/Meta分析,纳入35项随机对照试验(RCT)。
- 检索数据库包括PubMed、Cochrane Library、Embase、CNKI、CBM、VIP和万方数据,检索时间自建库至2018年3月4日。
- 采用RevMan 5.3软件进行Meta分析,漏斗图分析发表偏倚。
- 局限:纳入研究数量较少,文献偏倚不能完全排除。
对床旁实践的改变
- 作者认为血必净注射液可能通过较强的细胞因子清除、血小板提升和凝血改善来保护MODS患者器官功能,从而降低死亡率、改善预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To systematical evaluate the effect of Xuebijing injection in the treatment of multiple organ dysfunction syndrome (MODS).
METHODS: With the keywords including Xuebijing, multiple organ dysfunction syndrome, multiple organ dysfunction and multiple organ failure, PubMed, the Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), VIP and Wanfang Data from the database start until March 4th, 2018 were searched for relevant randomized controlled trials (RCTs) related to Xuebijing injection combined conventional treatment versus conventional treatment alone for MODS. The control group received conventional western medicine treatment, including etiological treatment, antibiotics, mechanical ventilation, nutritional support, and comprehensive treatment to maintain fluid, electrolyte, acid and alkali balance. The experimental group was given traditional western medicine combined with Xuebijing injection. The observation parameters included 7-day and 28-day mortality, acute physiology and chronic health evaluation II (APACHE II) and Marshall score, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), the number of platelets, activated partial thromboplastin time (APTT) and prothrombin time (PT). According to the inclusion and exclusion criteria, two evaluators independently screened the literature, extracted data and evaluated the methodological quality of the included studies. RevMan 5.3 software was used for Meta analysis. Funnel plot was used to analyze publication bias.
RESULTS: A total of 35 RCTs and 2 131 patients were enrolled, including 1 076 in the experimental group and 1 055 in the control group. The results of Meta analysis showed that compared with control group, Xuebijing combined conventional treatment was in favor to decrease the mortality of patients with MODS [7-day mortality: odds ratio (OR) = 0.42, 99% confidence interval (99%CI) = 0.26-0.69, P < 0.000 01; 28-day mortality: OR = 0.31, 99%CI = 0.21-0.45, P < 0.000 01], also could obviously reduce critical condition degree of APACHE II score and the organ function of Marshall score [APACHE II: mean difference (MD) = 3.24, 99%CI = 2.00-4.49, P < 0.000 01; Marshall score: MD = 1.95, 99%CI = 0.50-3.40, P = 0.000 5]. Meanwhile, the results of conventional western medicine combined with Xuebijing in the removal of IL-6 and TNF-α, platelets increase and improvement of PT were better than those of conventional western medicine (IL-6: MD = 5.56, 99%CI = 1.44-9.68, P = 0.000 5; TNF-α: MD = 4.97, 99%CI = 3.44-6.50, P < 0.000 01; platelets: MD = -50.79, 99%CI = -74.84 to -26.74, P < 0.000 1; PT: MD = 4.55, 99%CI = 3.96-5.14, P < 0.000 01), however, there was no obvious advantage in improving APTT (MD = 0.96, 99%CI = -5.08-7.00, P = 0.68). The analysis of funnel map showed that the effect points of various studies were mainly centered on the amount of combined effect, and the "inverted funnel" type was generally symmetrical distribution. However, because the number of the included studies was less, the literature bias could not be completely eliminated.
CONCLUSIONS: Xuebijing injection may through its strong cytokines clearance, platelet increase and blood coagulation improvement to protect the organ function in patients with MODS, so as to reduce the mortality and improve the prognosis.
参考来源
- Song R, Dong C, Wang C, et al. [Effectiveness of Xuebijing in treatment of multiple organ dysfunction syndrome: a Meta analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 30309410. doi:10.3760/cma.j.issn.2095-4352.2018.09.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。